Investment case
BioCardia, Inc.
BCDA · 2 developments mapped · last assessed 2026-09-23
Market Ontology has mapped 2 macro, policy, and market developments to BioCardia, Inc. since 2026-09-23. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for BCDA yet, so no modelled value is shown. The BCDA valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run BCDA on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
BioCardia, Inc. Provides Update on FDA and PMDA Regulatory Submissions
Direct progress towards regulatory approval and commercialization for key product candidates. De-risking of clinical development.
· Moves probability of success for cardiamp and helix, time to market, future revenue projections
What changed, by assumption
- 2026-09-23BioCardia, Inc. Provides Update on FDA and PMDA Regulatory Submissions
- 2026-09-23BioCardia Confirms Timing for FDA Helix Pre-Submission and PMDA CardiAMP HF Submission
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-06-12 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-06-12 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-23 | BioCardia, Inc. Provides Update on FDA and PMDA Regulatory Submissions | Bullish | 1-3m | 0.80 |
| 2026-09-23 | BioCardia Confirms Timing for FDA Helix Pre-Submission and PMDA CardiAMP HF Submission | Bullish | 3-12m | 0.80 |